{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:28:29Z","timestamp":1792301309970,"version":"4.4.0"},"reference-count":256,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics. Despite these advancements, recent studies have reported that even after sustained virologic response (SVR), individuals with advanced liver disease\/cirrhosis at the time of DAA treatment may still face risks of HCC occurrence or recurrence. Based on this premise, this review tries to shed light on the multiple mechanisms that establish a tumorigenic environment, first, during chronic HCV infection and then, after eventual viral eradication by DAAs. Furthermore, it reviews evidence reported by recent observational studies stating that the use of DAAs is not associated with an increased risk of HCC development but rather, with a significantly lower chance of liver cancer compared with DAA-untreated patients. In addition, it seeks to provide some practical guidance for clinicians, helping them to manage HCC surveillance of patients who have achieved SVR with DAAs.<\/jats:p>","DOI":"10.3390\/v16121899","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T04:15:03Z","timestamp":1733804103000},"page":"1899","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence\/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-5416","authenticated-orcid":false,"given":"Carlo","family":"Smirne","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Crobu","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"},{"name":"Clinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-1718","authenticated-orcid":false,"given":"Irene","family":"Landi","sequence":"additional","affiliation":[{"name":"Emergency Medicine Department, Michele e Pietro Ferrero Hospital, 12060 Verduno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7453-2151","authenticated-orcid":false,"given":"Nicole","family":"Vercellino","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-7468","authenticated-orcid":false,"given":"Daria","family":"Apostolo","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David James","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7548-9731","authenticated-orcid":false,"given":"Rosalba","family":"Minisini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-0890","authenticated-orcid":false,"given":"Stelvio","family":"Tonello","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-940X","authenticated-orcid":false,"given":"Davide","family":"D\u2019Onghia","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ottobrelli","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5538","authenticated-orcid":false,"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bracco","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Santa Croce e Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5123-7767","authenticated-orcid":false,"given":"Luigi Maria","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Santa Croce e Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Campanini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-2624","authenticated-orcid":false,"given":"Alessandro Maria","family":"Berton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-6181","authenticated-orcid":false,"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, City of Health and Science University Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-0155","authenticated-orcid":false,"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sallam, M., and Khalil, R. (2024). Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms, 12.","DOI":"10.3390\/microorganisms12061035"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kao, Y., Liu, Y., Cheng, Y., Wen, Y., Hsieh, Y., Hsu, C., Su, C., Tai, J., Chen, Y., and Jeng, W. (2024). Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Viruses, 16.","DOI":"10.3390\/v16091485"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4254\/wjh.v14.i6.1053","article-title":"Impact of Direct-Acting Antiviral Regimens on Hepatic and Extrahepatic Manifestations of Hepatitis C Virus Infection","volume":"14","author":"Salama","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with Direct-Acting Antivirals for HCV Decreases but Does Not Eliminate the Risk of Hepatocellular Carcinoma","volume":"39","author":"Mendizabal","year":"2019","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3350\/cmh.2020.0018","article-title":"Unmet Needs of Chronic Hepatitis C in the Era of Direct-acting Antiviral Therapy","volume":"26","author":"Huang","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_6","unstructured":"The CDA Foundation (2024, November 08). Hepatitis C: The Polaris Observatory Dashboard. Available online: https:\/\/cdafound.org\/polaris\/dashboard\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41575-018-0026-5","article-title":"Management of Acute HCV Infection in the Era of Direct-Acting Antiviral Therapy","volume":"15","author":"Martinello","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/sdi.12097","article-title":"Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities","volume":"26","author":"Mbaeyi","year":"2013","journal-title":"Semin. Dial."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a036921","DOI":"10.1101\/cshperspect.a036921","article-title":"Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy","volume":"10","author":"Negro","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The Global Burden of Viral Hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","article-title":"HIV\/hepatitis C Coinfection Natural History and Disease Progression, a Review of the Most Recent Literature","volume":"6","author":"Hernandez","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11901-010-0060-4","article-title":"Current Concepts of HBV\/HCV Coinfection: Coexistence, but Not Necessarily in Harmony","volume":"9","author":"Jamma","year":"2010","journal-title":"Curr. Hepat. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JHC.S221187","article-title":"Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment","volume":"7","author":"Dash","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","article-title":"Disease Burden of Hepatocellular Carcinoma: A Global Perspective","volume":"64","author":"Sayiner","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative Stress in Non-Alcoholic Fatty Liver Disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Livers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the Worldwide Hepatocellular Carcinoma: Epidemiology, Prevention and Management","volume":"12","author":"Samant","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing Etiology and Epidemiology of Hepatocellular Carcinoma: Asia and Worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_20","unstructured":"World Health Organization (2024, September 19). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jvh.13523","article-title":"Liver and Cardiovascular Mortality after Hepatitis C Virus Eradication by DAA: Data from RESIST-HCV Cohort","volume":"28","author":"Calvaruso","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v26.i22.2931","article-title":"Liver-Related Effects of Chronic Hepatitis C Antiviral Treatment","volume":"26","author":"Laursen","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV Reduces Viral Hepatitis-Associated Liver-Related Mortality in Patients: An ERCHIVES Study","volume":"73","author":"Butt","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of Direct-Acting Antiviral Therapy with Liver and Nonliver Complications and Long-Term Mortality in Patients with Chronic Hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e29432","DOI":"10.1002\/jmv.29432","article-title":"Non-Liver-Related Mortality in the DAA Era: Insights from Post-SVR Patients with and without Previous HCC History","volume":"96","author":"Miuma","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jvh.12866","article-title":"Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors\u2014A Systematic Review and Meta-Analysis","volume":"25","author":"Aisyah","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic Variation in IL28B and Spontaneous Clearance of Hepatitis C Virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus","volume":"62","author":"Chung","year":"2015","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1743-422X-7-296","article-title":"Hepatitis C Treatment: Current and Future Perspectives","volume":"7","author":"Munir","year":"2010","journal-title":"Virol. J."},{"key":"ref_30","first-page":"50","article-title":"IL28B Polymorphism, Blood Interferon-Alpha Concentration, and Disease Stage of HCV Mono-Infected and HCV-HIV Co-Infected Patients","volume":"11","author":"Burlone","year":"2013","journal-title":"Curr. HIV Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral Direct-Acting Agent Therapy for Hepatitis c Virus Infection: A Systematic Review","volume":"166","author":"Nelson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_32","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and The American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America HCV Guidance Panel (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jgh.12028","article-title":"Current Prospects for Interferon-Free Treatment of Hepatitis C in 2012","volume":"28","author":"Stedman","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jgh.13747","article-title":"Hepatitis C Treatment from \u201cResponse-Guided\u201d to \u201cResource-Guided\u201d Therapy in the Transition Era from Interferon-Containing to Interferon-Free Regimens","volume":"32","author":"Yu","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/apt.14507","article-title":"Systematic Review with Meta-Analysis: Effectiveness and Tolerability of Interferon-Free Direct-Acting Antiviral Regimens for Chronic Hepatitis C Genotype 1 in Routine Clinical Practice in Asia","volume":"47","author":"Ji","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3350\/cmh.2016.0052","article-title":"Barriers to Treatment of Failed or Interferon Ineligible Patients in the Era of DAA: Single Center Study","volume":"23","author":"Seo","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/14656566.2024.2396024","article-title":"Cutting-Edge Pharmacotherapy for Hepatitis C Virus Infection: A Comprehensive Review","volume":"25","author":"Liu","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5152\/eurasianjmed.2022.20421","article-title":"Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients","volume":"54","author":"Smirne","year":"2022","journal-title":"Eurasian J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s10620-024-08393-x","article-title":"Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis","volume":"69","author":"Pearlman","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00811","DOI":"10.1002\/prp2.811","article-title":"Sofosbuvir-Based Therapies in Genotype 2 Hepatitis C Virus Cirrhosis: A Real-Life Experience with Focus on Ribavirin Dose","volume":"9","author":"Smirne","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical Outcomes Following DAA Therapy in Patients with HCV-Related Cirrhosis Depend on Disease Severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_42","first-page":"143","article-title":"Treatment of Chronic Hepatitis C in Patients with Cirrhosis","volume":"32","author":"Chen","year":"2016","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2016.07.001","article-title":"Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis","volume":"14","author":"Maan","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.12.002","article-title":"Sofosbuvir and Ribavirin for Genotype 2 HCV Infected Patients with Cirrhosis: A Real Life Experience","volume":"66","author":"Mangia","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s43440-024-00639-9","article-title":"Real-World Experience with Direct-Acting Antiviral Therapy in HCV-Infected Patients with Cirrhosis and Esophageal Varices","volume":"76","author":"Kukla","year":"2024","journal-title":"Pharmacol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pugliese, N., Polverini, D., Arcari, I., De Nicola, S., Colapietro, F., Masetti, C., Ormas, M., Ceriani, R., Lleo, A., and Aghemo, A. (2023). Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life. Trop. Med. Infect. Dis., 8.","DOI":"10.3390\/tropicalmed8110502"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Smirne, C., Crobu, M.G., Gerevini, C., Berton, A.M., Rapetti, R., Pasini, B., Ravanini, P., and Pirisi, M. (2024). The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study. Genes, 15.","DOI":"10.3390\/genes15091116"},{"key":"ref_48","first-page":"e45680","article-title":"Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients with End-Stage Renal Disease Undergoing Hemodialysis","volume":"15","author":"Shahid","year":"2023","journal-title":"Cureus"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3892\/etm.2023.12100","article-title":"Direct-acting Antiviral Treatment Is Safe and Effective for Chronic HCV Patients with Psychiatric Disorders","volume":"26","author":"Okano","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gualerzi, A., Bellan, M., Smirne, C., Tran Minh, M., Rigamonti, C., Burlone, M.E., Bonometti, R., Bianco, S., Re, A., and Favretto, S. (2018). Improvement of Insulin Sensitivity in Diabetic and Non Diabetic Patients with Chronic Hepatitis C Treated with Direct Antiviral Agents. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0209216"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jvh.13750","article-title":"Safe Co-Administration of Direct-Acting Antivirals and Direct Oral Anticoagulants among Patients with Hepatitis C Virus Infection: An International Multicenter Retrospective Cohort Study","volume":"29","author":"McDaniel","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Czarnecka, P., Czarnecka, K., Tronina, O., B\u0105czkowska, T., Wycza\u0142kowska-Tomasik, A., Durlik, M., and Czerwinska, K. (2023). Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103513"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Patauner, F., Stanzione, M., Stornaiuolo, G., Martone, V., Palladino, R., Coppola, N., Durante-Mangoni, E., and Zampino, R. (2022). Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series. Pathogens, 11.","DOI":"10.3390\/pathogens11080860"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Crobu, M.G., Ravanini, P., Impaloni, C., Martello, C., Bargiacchi, O., Di Domenico, C., Faolotto, G., Macaluso, P., Mercandino, A., and Riggi, M. (2024). Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection. Viruses, 16.","DOI":"10.3390\/v16060992"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/agm2.12190","article-title":"Safety and Efficacy of Directly-Acting Antiviral Therapy for Chronic Hepatitis C Virus in Elderly People","volume":"4","author":"Maggi","year":"2021","journal-title":"Aging Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/MEG.0000000000002003","article-title":"Real-World Efficacy and Safety of Direct-Acting Antiviral Drugs in Patients with Chronic Hepatitis C and Inherited Blood Disorders","volume":"33","author":"Ruiz","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"An, J.H., Park, D.A., Ko, M.J., Ahn, S.B., Yoo, J.J., Jun, D.W., and Yim, S.Y. (2022). Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091517"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/ajt.16427","article-title":"Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antivirals in HIV\/HCV-Coinfected Participants with Decompensated Liver Disease Pre\u2013 or Post\u2013Liver Transplant","volume":"21","author":"Peters","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA Therapy and Long-Term Hepatic Function in Advanced\/Decompensated Cirrhosis: Real-World Experience from HCV-TARGET Cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dietz, C., and Maasoumy, B. (2022). Direct-Acting Antiviral Agents for Hepatitis C Virus Infection\u2014From Drug Discovery to Successful Implementation in Clinical Practice. Viruses, 14.","DOI":"10.3390\/v14061325"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Smith-Palmer, J., Cerri, K., and Valentine, W. (2015). Achieving Sustained Virologic Response in Hepatitis C: A Systematic Review of the Clinical, Economic and Quality of Life Benefits. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0748-8"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of Disease Manifestations after HCV Eradication","volume":"65","author":"Berenguer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time Association Between Hepatitis C Therapy and Hepatocellular Carcinoma Emergence in Cirrhosis: Relevance of Non-Characterized Nodules","volume":"70","author":"Darnell","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"The French METAVIR Cooperative Study Group (1994). Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C. Hepatology, 20, 15\u201320.","DOI":"10.1016\/0270-9139(94)90128-7"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3350\/cmh.2018.1002","article-title":"Recent Update of the 2017 Korean Association for the Study of the Liver (KASL) Treatment Guidelines of Chronic Hepatitis C: Comparison of Guidelines from Other Continents, 2017 AASLD\/IDSA and 2016 EASL","volume":"24","author":"Yeon","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_70","first-page":"305","article-title":"Management of Patients Who Have Achieved Sustained Virologic Response for Hepatitis C Virus Infection","volume":"14","author":"Pockros","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/j.gastro.2012.01.045","article-title":"Is Hepatitis C Virus Carcinogenic?","volume":"142","author":"Lemon","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"28","DOI":"10.20517\/2394-5079.2022.08","article-title":"Impact of Direct-Acting Antivirals on the Recurrence of Hepatocellular Carcinoma in Chronic Hepatitis C","volume":"8","author":"Tagkou","year":"2022","journal-title":"Hepatoma Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends","volume":"72","author":"Singal","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_75","unstructured":"Global Burden of Disease Liver Cancer Collaboration, Abera, S., Ahmed, M., Alam, N., Alemayohu, M.A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., and Artaman, A. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level Results from the Global Burden of Disease Study 2015. JAMA Oncol., 3, 1683\u20131691."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4251\/wjgo.v16.i3.761","article-title":"Epidemiology, Therapy and Outcome of Hepatocellular Carcinoma between 2010 and 2019 in Piedmont, Italy","volume":"16","author":"Bracco","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Grgurevic, I., Bozin, T., Mikus, M., Kukla, M., and O\u2019beirne, J. (2021). Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers, 13.","DOI":"10.3390\/cancers13225844"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of Liver Diseases in the World","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/jnci\/djr395","article-title":"Hepatocellular Carcinoma Risk Factors and Disease Burden in a European Cohort: A Nested Case-Control Study","volume":"103","author":"Trichopoulos","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.15464","article-title":"Characteristics, Aetiologies and Trends of Hepatocellular Carcinoma in Patients Without Cirrhosis: A United States Multicentre Study","volume":"50","author":"Gawrieh","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of Blood Transfusion, Non-A, Non-B Hepatitis and Hepatocellular Carcinoma: Analysis by Detection of Antibody to Hepatitis C Virus","volume":"12","author":"Kiyosawa","year":"1990","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.gastro.2004.09.012","article-title":"Hepatocellular Carcinoma: Recent Trends in Japan","volume":"127","author":"Kiyosawa","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.1840120323","article-title":"Hepatitis C-Associated Hepatocellular Carcinoma","volume":"12","author":"Hasan","year":"1990","journal-title":"Hepatology"},{"key":"ref_88","first-page":"335","article-title":"The Role of Chronic Viral Hepatitis in Hepatocellular Carcinoma in the United States","volume":"86","author":"Order","year":"1991","journal-title":"Am. J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jmv.1890430205","article-title":"Use of Confirmatory Assays for Diagnosis of Hepatitis C Viral Infection in Patients with Hepatocellular Carcinoma","volume":"43","author":"Mangia","year":"1994","journal-title":"J. Med. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-199410000-00011","article-title":"Development of Hepatocellular Carcinoma among Patients with Chronic Liver Disease due to Hepatitis C Viral Infection","volume":"19","author":"Simpson","year":"1994","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ijc.2910540407","article-title":"Tumor-suppressor P53 Gene in Hepatitis C and B Virus-associated Human Hepatocellular Carcinoma","volume":"54","author":"Shieh","year":"1993","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cam4.1998","article-title":"Real Impact of Liver Cirrhosis on the Development of Hepatocellular Carcinoma in Various Liver Diseases\u2014Meta-Analytic Assessment","volume":"8","author":"Tarao","year":"2019","journal-title":"Cancer Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1002\/hep.510260706","article-title":"Hepatitis C and Hepatocellular Carcinoma","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-017-0138-5","article-title":"Frequency and Geographic Distribution of TERT Promoter Mutations in Primary Hepatocellular Carcinoma","volume":"12","author":"Pezzuto","year":"2017","journal-title":"Infect. Agents Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and P53 Pathways in Cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., and Omata, M. (2019). Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061358"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Komposch, K., and Sibilia, M. (2016). EGFR Signaling in Liver Diseases. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010030"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal Role of MTOR Signaling in Hepatocellular Carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","article-title":"The Role of Signaling Pathways in the Development and Treatment of Hepatocellular Carcinoma","volume":"29","author":"Whittaker","year":"2010","journal-title":"Oncogene"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"12292","DOI":"10.1128\/JVI.05920-11","article-title":"Hepatitis C Virus-Induced Cancer Stem Cell-Like Signatures in Cell Culture and Murine Tumor Xenografts","volume":"85","author":"Ali","year":"2011","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1073\/pnas.0807390106","article-title":"Toll-like Receptor 4 Mediates Synergism between Alcohol and HCV in Hepatic Oncogenesis Involving Stem Cell Marker Nanog","volume":"106","author":"Machida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.yexmp.2010.01.002","article-title":"DNA Methylation Changes in Normal Liver Tissues and Hepatocellular Carcinoma with Different Viral Infection","volume":"88","author":"Feng","year":"2010","journal-title":"Exp. Mol. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Iwai, A., Takegami, T., Shiozaki, T., and Miyazaki, T. (2011). Hepatitis C Virus NS3 Protein Can Activate the Notch-Signaling Pathway through Binding to a Transcription Factor, SRCAP. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020718"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.24576","article-title":"Up-Regulation of Hedgehog Pathway Is Associated with Cellular Permissiveness for Hepatitis C Virus Replication","volume":"54","author":"Choi","year":"2011","journal-title":"Hepatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep4.1025","article-title":"Interferon-Alpha-Induced Hepatitis C Virus Clearance Restores P53 Tumor Suppressor More than Direct-Acting Antivirals","volume":"1","author":"Aydin","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Hayashi, A., Yamauchi, N., Shibahara, J., Kimura, H., Morikawa, T., Ishikawa, S., Nagae, G., Nishi, A., Sakamoto, Y., and Kokudo, N. (2014). Concurrent Activation of Acetylation and Tri-Methylation of H3K27 in a Subset of Hepatocellular Carcinoma with Aggressive Behavior. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091330"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Aydin, Y., Kurt, R., Song, K., Lin, D., Osman, H., Youngquist, B., Scott, J.W., Shores, N.J., Thevenot, P., and Cohen, A. (2019). Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-MiR-122 Feedback Loop in Liver Fibrosis and Cancer Progression. Cancers, 11.","DOI":"10.3390\/cancers11101407"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune Responses to HCV and Other Hepatitis Viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/eji.200635989","article-title":"Increased Natural Cytotoxicity Receptor Expression and Relevant IL-10 Production in NK Cells from Chronically Infected Viremic HCV Patients","volume":"37","author":"Fogli","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0198-8859(02)00781-4","article-title":"Lack of Optimal T-Cell Reactivity Against the Hepatitis C Virus Is Associated with the Development of Fibrosis\/Cirrhosis During Chronic Hepatitis","volume":"64","author":"Sreenarasimhaiah","year":"2003","journal-title":"Hum. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Abdel-Hakeem, M.S., and Shoukry, N.H. (2014). Protective Immunity Against Hepatitis C: Many Shades of Gray. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00274"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e6508","DOI":"10.1097\/MD.0000000000006508","article-title":"Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma in Treatment-Na\u00efve Chronic Hepatitis C Patients in China","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14218\/JCTH.2015.00001","article-title":"Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-Alcoholic Fatty Liver Diseases","volume":"3","author":"Raff","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000343856","article-title":"Hepatic Iron Overload and Hepatocellular Carcinoma","volume":"3","author":"Kew","year":"2014","journal-title":"Liver Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/hep.27337","article-title":"Clinical Outcomes of Hepatitis B Virus Coinfection in a United States Cohort of Hepatitis C Virus-Infected Patients","volume":"60","author":"Kruse","year":"2014","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/liv.15253","article-title":"Hepatocellular Carcinoma: The Virus or the Liver?","volume":"43","author":"Papatheodoridi","year":"2023","journal-title":"Liver Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11904-019-00475-0","article-title":"Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies","volume":"17","author":"Merchante","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1995-7645(14)60100-0","article-title":"Toxoplasma Gondii Infection among Chronic Hepatitis C Patients: A Case-Control Study","volume":"7","author":"Farag","year":"2014","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women","volume":"155","author":"Donato","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.02.010","article-title":"Aflatoxin B1 Exposure Increases the Risk of Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection or Alcohol Consumption","volume":"94","author":"Chu","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Sinyuk, M., Mulkearns-Hubert, E.E., Reizes, O., and Lathia, J. (2018). Cancer Connectors: Connexins, Gap Junctions, and Communication. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00646"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.21037\/tcr.2019.04.01","article-title":"Direct Antiviral Agents for HCV Infection and Hepatocellular Carcinoma: Facts and FADs","volume":"8","author":"Serio","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Bang, C.S., and Song, I.H. (2017). Impact of Antiviral Therapy on Hepatocellular Carcinoma and Mortality in Patients with Chronic Hepatitis C: Systematic Review and Meta-Analysis. BMC Gastroenterol., 17.","DOI":"10.1186\/s12876-017-0606-9"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Rinaldi, L., Nevola, R., Franci, G., Perrella, A., Corvino, G., Marrone, A., Berretta, M., Morone, M.V., Galdiero, M., and Giordano, M. (2020). Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers, 12.","DOI":"10.3390\/cancers12061351"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/135965350601100811","article-title":"A Sustained Virological Response to Interferon or Interferon\/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan","volume":"11","author":"Yu","year":"2006","journal-title":"Antivir. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","article-title":"Long-Term Effect of Sustained Virological Response on Hepatocellular Carcinoma in Patients with Hepatitis C in Canada","volume":"66","author":"Janjua","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2014.02.022","article-title":"Baseline Gamma-Glutamyl Transferase Levels Strongly Correlate with Hepatocellular Carcinoma Development in Non-Cirrhotic Patients with Successful Hepatitis C Virus Eradication","volume":"61","author":"Huang","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of Hepatocellular Carcinoma after Sustained Virological Response in Veterans with Hepatitis C Virus Infection","volume":"64","author":"Kanwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3350\/cmh.2018.0108","article-title":"Development and Surveillance of Hepatocellular Carcinoma in Patients with Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C","volume":"25","author":"Na","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association Between Sustained Virological Response and All-Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and Prevention of Hepatocellular Carcinoma in Viral Cirrhosis: An Evidence-Based Approach","volume":"34","author":"Giunta","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_135","first-page":"3","article-title":"Response Rates to Direct Antiviral Agents Among Hepatitis C Virus Infected Patients Who Develop Hepatocellular Carcinoma Following Direct Antiviral Agents Treatment","volume":"6","author":"Burlone","year":"2020","journal-title":"Hepatoma Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of Cirrhosis-Related Complications in Patients with Advanced Fibrosis Following Hepatitis C Virus Eradication","volume":"66","author":"Feld","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained Virological Response to Interferon-\u03b1 Is Associated with Improved Outcome in HCV-Related Cirrhosis: A Retrospective Study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","article-title":"Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival","volume":"142","author":"Shiratori","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A Risk for Hepatocellular Carcinoma Persists Long-Term After Sustained Virologic Response in Patients with Hepatitis C\u2014Associated Liver Cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A Sustained Viral Response Is Associated with Reduced Liver-Related Morbidity and Mortality in Patients with Hepatitis C Virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jgh3.12805","article-title":"Risk Factors for Liver-Related Mortality of Patients with Hepatitis C Virus after Sustained Virologic Response to Direct-Acting Antiviral Agents","volume":"6","author":"Hattori","year":"2022","journal-title":"JGH Open"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijsu.2020.01.145","article-title":"Liver Transplantation for Hepatitis C Patients in the Era of Direct-Acting Antiviral Treatment: A Retrospective Cohort Study","volume":"75","author":"Khan","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on Liver Transplantation: Major Effects on the Evolution of Indications and Results. An ELITA Study Based on the ELTR Registry","volume":"69","author":"Belli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"237","DOI":"10.12968\/jowc.2010.19.6.48471","article-title":"Outcomes in Controlled and Comparative Studies on Non-Healing Wounds: Recommendations to Improve the Quality of Evidence in Wound Management","volume":"19","author":"Gottrup","year":"2010","journal-title":"J. Wound Care"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","article-title":"Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C","volume":"129","author":"Imai","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(96)80022-5","article-title":"Alpha Interferon Treatment May Prevent Hepatocellular Carcinoma in HCV-Related Liver Cirrhosis","volume":"24","author":"Mazzella","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","article-title":"Randomised Trial of Effects of Interferon-\u03b1 on Incidence of Hepatocellular Carcinoma in Chronic Active Hepatitis C with Cirrhosis","volume":"346","author":"Nishiguchi","year":"1995","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0168-8278(00)80308-6","article-title":"Interferon-Induced Gene Expression and Signaling in Human Hepatoma Cell Lines","volume":"33","author":"Keskinen","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1348-0421.1988.tb01476.x","article-title":"Suppression of HBsAg Production in PLC\/PRF\/5 Human Hepatoma Cell Line by Interferons","volume":"32","author":"Yamashita","year":"1988","journal-title":"Microbiol. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13651820410024030","article-title":"Prevention of Hepatocellular Carcinoma","volume":"7","author":"Kew","year":"2005","journal-title":"HPB"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"31","DOI":"10.20517\/2394-5079.2019.19","article-title":"No Evidence for Higher Rates of Hepatocellular Carcinoma after Direct-Acting Antiviral Treatment: A Meta-Analysis","volume":"2019","author":"Rutledge","year":"2019","journal-title":"Hepatoma Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e2420963","DOI":"10.1001\/jamanetworkopen.2024.20963","article-title":"Screening for Hepatocellular Carcinoma and Survival in Patients with Cirrhosis After Hepatitis C Virus Cure","volume":"7","author":"Mezzacappa","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jfma.2024.01.015","article-title":"Risk of Hepatocellular Carcinoma After Viral Clearance Achieved by DAA Treatment","volume":"123","author":"Maekawa","year":"2024","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ags3.12725","article-title":"Trends in Long-Term Outcomes of Patients with HCV-Associated Hepatocellular Carcinoma After Hepatectomy: A Comparison Before and After Introduction of Direct-Acting Antivirus Therapy","volume":"8","author":"Munekage","year":"2024","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Radu, P., Becchetti, C., Schropp, J., Schmid, P., K\u00fcnzler-Heule, P., Mertens, J., Moradpour, D., M\u00fcllaupt, B., Semela, D., and Negro, F. (2024). Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection. Cancers, 16.","DOI":"10.3390\/cancers16142573"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly Diagnosed Hepatocellular Carcinoma in Patients with Advanced Hepatitis C Treated with DAAs: A Prospective Population Study","volume":"69","author":"Romano","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients with HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually High Rates of Hepatocellular Carcinoma After Treatment with Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000450551","article-title":"Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis Following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals","volume":"91","author":"Akuta","year":"2016","journal-title":"Oncology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, Safety and Clinical Outcomes of Direct-Acting Antiviral Therapy in HCV Genotype 1 Infection: Results from a Spanish Real-World Cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV Eradication Induced by Direct-Acting Antiviral Agents Reduces the Risk of Hepatocellular Carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The Risk of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis C and Sustained Viral Response: Role of the Treatment Regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased after Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Quaranta, M., Cavalletto, L., Russo, F., Calvaruso, V., Ferrigno, L., Zanetto, A., Mattioli, B., D\u2019Ambrosio, R., Panetta, V., and Brancaccio, G. (2024). Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV). Viruses, 16.","DOI":"10.3390\/v16050682"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s12072-024-10700-7","article-title":"Risk of Hepatocellular Carcinoma Occurrence After Antiviral Therapy for Patients with Chronic Hepatitis C Infection: A Systematic Review and Meta-Analysis","volume":"18","author":"Lv","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/apt.17863","article-title":"Racial and Ethnic Disparities in Untreated Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma but Not in Those with Sustained Virologic Response","volume":"59","author":"Park","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s12029-024-01076-w","article-title":"Impact of DAA Treatment for HCV on Hepatocellular Carcinoma in a Predominately African American Population","volume":"55","author":"Itani","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.57187\/s.3698","article-title":"Real-Life Experience of Chronic Hepatitis C Treatment in Switzerland: A Retrospective Analysis","volume":"154","author":"Moschouri","year":"2024","journal-title":"Swiss Med. Wkly."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High Incidence of Hepatocellular Carcinoma Following Successful Interferon-Free Antiviral Therapy for Hepatitis C Associated Cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Zhao, P., Malik, S., and Xing, S. (2021). Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.677926"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2741\/2060","article-title":"Molecular Pathogenesis of Hepatitis C Virus-Associated Hepatocellular Carcinoma","volume":"12","author":"Jin","year":"2007","journal-title":"Front. Biosci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4254\/wjh.v10.i9.595","article-title":"Hepatocellular Carcinoma Occurrence in DAA-Treated Hepatitis C Virus Patients: Correlated or Incidental? A Brief Review","volume":"10","author":"Gigi","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jare.2019.03.001","article-title":"Impact of Treating Chronic Hepatitis C Infection with Direct-Acting Antivirals on the Risk of Hepatocellular Carcinoma: The Debate Continues\u2014A Mini-Review","volume":"17","author":"Elbaz","year":"2019","journal-title":"J. Adv. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3748\/wjg.v24.i24.2582","article-title":"Direct-Acting Antivirals and Hepatocellular Carcinoma in Chronic Hepatitis C: A Few Lights and Many Shadows","volume":"24","author":"Guarino","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2169\/internalmedicine.3382-19","article-title":"Influence of Interferon-Free Direct-Acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-Dependent Extended Cox Proportional Hazards Model Analysis","volume":"59","author":"Miuma","year":"2020","journal-title":"Intern. Med."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Frazzoni, L., Sikandar, U., Metelli, F., Sadalla, S., Mazzella, G., Bazzoli, F., Fuccio, L., and Azzaroli, F. (2021). Hepatocellular Carcinoma Recurrence After Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081694"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.3748\/wjg.v26.i43.6770","article-title":"Hepatocellular Carcinoma after Direct-Acting Antiviral Hepatitis C Virus Therapy: A Debate near the End","volume":"26","author":"Muzica","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3350\/cmh.2017.0074","article-title":"Interferon-Free Treatment for Hepatitis c Virus Infection Induces Normalization of Extrahepatic Type i Interferon Signaling","volume":"24","author":"Sung","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Iuliano, M., Mangino, G., Chiantore, M.V., Di Bonito, P., Rosa, P., Affabris, E., and Romeo, G. (2021). Virus-Induced Tumorigenesis and IFN System. Biology, 10.","DOI":"10.3390\/biology10100994"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of Type-I- and Type-II-Interferon-Mediated Signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Villani, R., Facciorusso, A., Bellanti, F., Tamborra, R., Piscazzi, A., Landriscina, M., Vendemiale, G., and Serviddio, G. (2016). DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk During Anti-HCV Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167934"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000536154","article-title":"Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma Following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents","volume":"102","author":"Suzuki","year":"2024","journal-title":"Oncology"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Babic, M., and Romagnani, C. (2018). The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01219"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Chu, P.S., Nakamoto, N., Taniki, N., Ojiro, K., Amiya, T., Makita, Y., Murata, H., Yamaguchi, A., Shiba, S., and Miyake, R. (2017). On-Treatment Decrease of NKG2D Correlates to Early Emergence of Clinically Evident Hepatocellular Carcinoma After Interferon-Free Therapy for Chronic Hepatitis C. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179096"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Perez, S., Kaspi, A., Domovitz, T., Davidovich, A., Lavi-Itzkovitz, A., Meirson, T., Holmes, J.A., Dai, C.Y., Huang, C.F., and Chung, R.T. (2019). Hepatitis C Virus Leaves an Epigenetic Signature Post Cure of Infection by Direct-Acting Antivirals. PLoS Genet., 15.","DOI":"10.1371\/journal.pgen.1008181"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-Induced Epigenetic Changes Associated with Liver Cancer Risk Persist After Sustained Virologic Response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.21037\/tcr-20-3385","article-title":"Prognostic and Diagnostic Value of SOX9 in Cirrhotic and Noncirrhotic Hepatocellular Carcinoma","volume":"10","author":"Xu","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10409238.2017.1337706","article-title":"Sphingosine Kinase and Sphingosine-1-Phosphate in Liver Pathobiology","volume":"52","author":"Rohrbach","year":"2017","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s12094-022-02859-y","article-title":"HCV Core Protein Represses DKK3 Expression via Epigenetic Silencing and Activates the Wnt\/\u03b2-Catenin Signaling Pathway during the Progression of HCC","volume":"24","author":"Wang","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"3000605221074525","DOI":"10.1177\/03000605221074525","article-title":"Integrated Analysis of Differentially Expressed Genes, Differentially Methylated Genes, and Natural Compounds in Hepatitis C Virus-Induced Cirrhosis","volume":"50","author":"Cheng","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Lin, D., Reddy, V., Osman, H., Lopez, A., Koksal, A.R., Rhadhi, S.M., Dash, S., and Aydin, Y. (2021). Additional Inhibition of Wnt\/\u03b2-Catenin Signaling by Metformin in Daa Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients. Cells, 10.","DOI":"10.3390\/cells10040790"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12964-023-01081-9","article-title":"Targeting ER Stress\/PKA\/GSK-3\u03b2\/\u03b2-Catenin Pathway as a Potential Novel Strategy for Hepatitis C Virus-Infected Patients","volume":"21","author":"Lin","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"23683","DOI":"10.3390\/ijms161023683","article-title":"Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection","volume":"16","author":"Sung","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coi.2015.03.002","article-title":"New Insights into Type I Interferon and the Immunopathogenesis of Persistent Viral Infections","volume":"34","author":"Snell","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous Intrahepatic IFNs and Association with IFN-Free HCV Treatment Outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00005-018-0532-8","article-title":"Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy","volume":"67","author":"Urbanowicz","year":"2019","journal-title":"Arch Immunol. Ther. Exp."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I Interferon in Chronic Virus Infection and Cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Sung, P.S., and Jang, J.W. (2018). Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201810.0450.v1"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Sajid, M., Liu, L., and Sun, C. (2022). The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.887186"},{"key":"ref_205","first-page":"1117","article-title":"Direct-Acting Antiviral-Induced Transient Recovery of NK Cells in Early-Stage Treatment of Chronic Hepatitis C Patients","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4161\/epi.4.5.9371","article-title":"Epigenetic Disruption of the WNT\/Beta-Catenin Signaling Pathway in Human Cancers","volume":"4","author":"Ying","year":"2009","journal-title":"Epigenetics"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC Surveillance After SVR in Patients with F3\/F4 Fibrosis","volume":"74","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Abu-Freha, N., Abu-Kosh, O., Yardeni, D., Ashur, Y., Abu-Arar, M., Yousef, B., Monitin, S., Weissmann, S., and Etzion, O. (2023). Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents. Life, 13.","DOI":"10.3390\/life13091872"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"29","DOI":"10.20517\/2394-5079.2022.13","article-title":"Changes in Hepatic Fibrosis and Incidence of HCC Following Direct-Acting Antiviral Treatment of F3 Chronic Hepatitis c Patients: A Prospective Observational Study","volume":"8","author":"Shiha","year":"2022","journal-title":"Hepatoma Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in Chronic Hepatitis C Patients with Advanced Hepatic Fibrosis Who Achieved SVR Following DAAs: A Prospective Study","volume":"27","author":"Shiha","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_211","unstructured":"Nahon, P., lusivka-Nzinga, C., Merle, P., Zoulim, F., Decaens, T., Ganne-Carri\u00e9, N., Pageaux, G., Leroy, V., Alric, L., and Bronowicki, J.P. (2024, January 5\u20138). Hepatocellular Carcinoma Development despite Histological Regression of Liver Fibrosis Following HCV Cure (ANRS CirVir, Hepather, LICAVIR). Proceedings of the European Association for the Study of the Liver (EASL) Congress 2024, Milan, Italy."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4254\/wjh.v14.i6.1120","article-title":"Fibrosis Regression Following Hepatitis C Antiviral Therapy","volume":"14","author":"Elsharkawy","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/hep4.1733","article-title":"Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication","volume":"5","author":"Ioannou","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JCMA.0000000000001051","article-title":"Analyzing Risk Factors and Developing a Stratification System for Hepatocellular Carcinoma Recurrence after Interferon-Free Direct-Acting Antiviral Therapy in Chronic Hepatitis C Patients","volume":"87","author":"Luan","year":"2024","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_216","unstructured":"(2024, October 03). American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing and Treating Hepatitis C. Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy. Available online: https:\/\/www.hcvguidelines.org\/evaluate\/monitoring."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV Guidelines of Virus-Eradicated Patients by DAA on How to Monitor HCC Occurrence and HBV Reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/jgh.16553","article-title":"Changes in Clinical Outcomes in Japanese Patients with Hepatocellular Carcinoma Due to Hepatitis C Virus Following the Development of Direct-Acting Antiviral Agents","volume":"39","author":"Ohama","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/apt.18199","article-title":"Impact of HCV Eradication on Recurrence Pattern and Long-Term Outcomes in Patients with HCV-Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation","volume":"60","author":"Wu","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_220","first-page":"116","article-title":"The Relationship between Hepatocellular Carcinoma and Hepatitis B and C Virus","volume":"14","author":"Kohli","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"13596535231189644","DOI":"10.1177\/13596535231189643","article-title":"Hepatitis C Virus\/Hepatitis B Virus Coinfection: Current Prospectives","volume":"28","author":"Maqsood","year":"2023","journal-title":"Antivir. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"296","DOI":"10.14218\/JCTH.2018.00016","article-title":"HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation","volume":"6","author":"Mavilia","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9270(00)02167-5","article-title":"Hepatocellular Carcinoma in HIV-Infected Patients with Chronic Hepatitis C","volume":"96","author":"Rodriguez","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and Outcome of Hepatocellular Carcinoma in HIV-Infected Patients: A U.S.\u2013Canadian Multicenter Study","volume":"47","author":"Fox","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1093\/infdis\/jiaa279","article-title":"Insights into the Pathophysiology of Liver Disease in HCV\/HIV: Does It End with HCV Cure?","volume":"222","author":"Jeyarajan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Stasi, C., and Brillanti, S. (2024). Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis Before and After Direct-Acting Antivirals. Microorganisms, 12.","DOI":"10.3390\/microorganisms12071418"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.22870","article-title":"Prospective Risk Assessment for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C by Transient Elastography","volume":"49","author":"Masuzaki","year":"2009","journal-title":"Hepatology"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Nakai, M., Yamamoto, Y., Baba, M., Suda, G., Kubo, A., Tokuchi, Y., Kitagataya, T., Yamada, R., Shigesawa, T., and Suzuki, K. (2022). Prediction of Hepatocellular Carcinoma Using Age and Liver Stiffness on Transient Elastography after Hepatitis C Virus Eradication. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-05492-5"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3748\/wjg.v30.i10.1450","article-title":"Shear-Wave Elastography to Predict Hepatocellular Carcinoma After Hepatitis C Virus Eradication: A Systematic Review and Meta-Analysis","volume":"30","author":"Esposto","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13027-024-00578-3","article-title":"Development and Validation of a Nomogram for Assessing Hepatocellular Carcinoma Risk After SVR in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis","volume":"19","author":"Xu","year":"2024","journal-title":"Infect. Agents Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"100381","DOI":"10.1016\/j.clinsp.2024.100381","article-title":"Noninvasive Assessment of Liver Fibrosis Can Predict Clinical Outcomes at Late Follow-up After a Sustained Virological Response in HCV Patients?","volume":"79","author":"Ragazzo","year":"2024","journal-title":"Clinics"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cgh.2023.11.020","article-title":"Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans with Cirrhosis","volume":"22","author":"John","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.dld.2023.04.018","article-title":"Dynamics of Liver Stiffness Predicts Complications in Patients with HCV Related Cirrhosis Treated with Direct-Acting Antivirals","volume":"55","author":"Nicoletti","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00535-016-1228-7","article-title":"Prediction of Development of Hepatocellular Carcinoma Using a New Scoring System Involving Virtual Touch Quantification in Patients with Chronic Liver Diseases","volume":"52","author":"Aoki","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10396-023-01398-5","article-title":"VFMAP Predicted Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C Who Were Treated with Direct-Acting Antiviral and Achieved Sustained Virologic Response","volume":"51","author":"Matono","year":"2024","journal-title":"J. Med. Ultrason."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"HEP21","DOI":"10.2217\/hep-2020-0010","article-title":"HCC Occurrence After DAA Treatments: Molecular Tools to Assess the Post-Treatment Risk and Surveillance","volume":"7","author":"Pascut","year":"2020","journal-title":"Hepatic Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000486590","article-title":"A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients","volume":"36","author":"Zou","year":"2018","journal-title":"Dig. Dis."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1053\/j.gastro.2011.02.058","article-title":"Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C","volume":"140","author":"Vergniol","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"AMAP Risk Score Predicts Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Schotten, C., Ostertag, B., Sowa, J.P., Manka, P., Bechmann, L.P., Hilgard, G., Marquardt, C., Wichert, M., Toyoda, H., and Lange, C.M. (2021). Galad Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis b and c Patients. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080735"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1007\/s10620-020-06550-6","article-title":"Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers","volume":"65","author":"Deng","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of Galadus Score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jvh.13717","article-title":"International Multicenter Validation of GES Score for HCC Risk Stratification in Chronic Hepatitis C Patients","volume":"29","author":"Shiha","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/liv.14666","article-title":"GES: A Validated Simple Score to Predict the Risk of HCC in Patients with HCV-GT4-Associated Advanced Liver Fibrosis after Oral Antivirals","volume":"40","author":"Shiha","year":"2020","journal-title":"Liver Int."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1111\/liv.14995","article-title":"Development of a Simple Dynamic Algorithm for Individualized Hepatocellular Carcinoma Risk-Based Surveillance Using Pre- and Post-Treatment General Evaluation Score","volume":"41","author":"Shiha","year":"2021","journal-title":"Liver Int."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.28832","article-title":"Risk Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis: The ADRESS-HCC Risk Model","volume":"120","author":"Flemming","year":"2014","journal-title":"Cancer"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Tokumoto, Y., Joko, K., Michitaka, K., Horiike, N., Tanaka, Y., Hiraoka, A., Tada, F., Ochi, H., and Kisaka, Y. (2023). Simple New Clinical Score to Predict Hepatocellular Carcinoma After Sustained Viral Response with Direct-Acting Antivirals. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36052-0"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jgh.16512","article-title":"MADRES Predicts Hepatocellular Carcinoma Development in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response","volume":"39","author":"Tada","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12072-021-10284-6","article-title":"Predictive Performance and Clinical Utility of HCC Risk Scores in Chronic Hepatitis C: A Comparative Study","volume":"16","author":"Shiha","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"e2015626","DOI":"10.1001\/jamanetworkopen.2020.15626","article-title":"Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients with Hepatitis C Cirrhosis","volume":"3","author":"Ioannou","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease Progression in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/RMHP.S18677","article-title":"Hepatocellular Carcinoma: Cost-Effectiveness of Screening. A Systematic Review","volume":"5","author":"Ruggeri","year":"2012","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"101582","DOI":"10.1016\/j.aohep.2024.101582","article-title":"Surveillance and Management of Hepatocellular Carcinoma After Treatment of Hepatitis C with Direct-Acting Antiviral Drugs","volume":"30","author":"Yang","year":"2024","journal-title":"Ann. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1899\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:05Z","timestamp":1760115065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":256,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["v16121899"],"URL":"https:\/\/doi.org\/10.3390\/v16121899","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}